SCHEMBL632596

SCHEMBL632596

COc1cccc(N)c1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
TDP1 Q9NUW8 3/20 0.60
ADRA2B P18089 1/20 0.60
PTGS1 P23219 1/20 0.60
KDM4E B2RXH2 3/20 0.47
MAPT P10636 3/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
CA4 P22748 1/20 0.46
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
BLM P54132 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15488393 0.98 ALDH1A1 (0.58) ALDH1A1TDP1ADRA2BPTGS1KDM4E
SCHEMBL630768 0.83 CA1 (0.58) ALDH1A1TDP1ADRA2BPTGS1KDM4E
SCHEMBL396830 0.82 ALDH1A1 (0.55) ALDH1A1TDP1ADRA2BPTGS1KDM4E
SCHEMBL19712987 0.79 ALDH1A1 (0.47) ALDH1A1TDP1ADRA2BPTGS1KDM4E
SCHEMBL1429875 0.79 IDO1 (0.48) ALDH1A1TDP1ADRA2BPTGS1KDM4E
SCHEMBL6828480 0.78 ALDH1A1 (0.50) ALDH1A1TDP1ADRA2BPTGS1KDM4E
SCHEMBL20294485 0.78 ALDH1A1 (0.46) ALDH1A1TDP1ADRA2BPTGS1KDM4E
SCHEMBL5205296 0.77 ALDH1A1 (0.64) ALDH1A1TDP1ADRA2BPTGS1KDM4E
SCHEMBL19878952 0.77 MCHR1 (0.46) ALDH1A1TDP1ADRA2BPTGS1KDM4E
SCHEMBL13537676 0.77 CYP1A2 (0.44) ALDH1A1TDP1ADRA2BPTGS1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087442-A1 AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 US disclosed
EP-4598933-A1 PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF Allorion Therapeutics Inc (US) 2025-08-13 EP disclosed
US-12338230-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-06-24 US disclosed
EP-4558511-A2 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF Firefly Bio, Inc. (US) 2025-05-28 EP disclosed
CN-119968377-A Phosphoramidate compounds and uses thereof 安锐生物医药公司 2025-05-09 CN disclosed
WO-2024238872-A2 ISOINDOLINONE-GLUTARIMIDE ANTIBODY CONJUGATES, AND USES THEREOF FIREFLY BIO, INC. (US) 2024-11-21 WO disclosed
US-20240368115-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHUJING BIOPHARMA CO., LTD (CN) 2024-11-07 US disclosed
WO-2024220236-A2 HYDROXYLAMINE-BASED BCR-ABL1 INHIBITORS FOR TREATMENT OF CANCER UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-10-24 WO disclosed
CN-114026073-B Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders ARRAY生物制药公司 2024-08-23 CN disclosed
WO-2004103996-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-12-02 WO disclosed
CN-1158238-C Haloacetophenone derivative and its synthesis process 大连绿源新化学药业股份有限公司 2004-07-21 CN disclosed
EP-1242406-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-03-17 EP disclosed
WO-2004011460-A2 PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS QLT, INC. (CA) 2004-02-05 WO disclosed
CN-1447797-A New process for preparing quinolone-carboxylic acid DALIAN LYNCHEM CO LTD (CN) 2003-10-08 CN disclosed
CN-1434818-A Novel compounds ASTRAZENECA AB (SE) 2003-08-06 CN disclosed
US-20030036552-A1 Novel compounds ASTRAZENECA AB (SE) 2003-02-20 US disclosed
EP-1242406-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-09-25 EP disclosed
CN-1320591-A Haloacetophenone derivative and its synthesis process LUYUAN INDUSTRY CO LTD DALIAN (CN) 2001-11-07 CN disclosed
WO-2001046263-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368115-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TPH1, TPH2, GAP43 ALDH1A1 2405/4885TDP1 1811/4885ADRA2B 54/4885
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof C5, DPYD, C9 ALDH1A1 1373/4885TDP1 173/4885ADRA2B 4482/4885
US-12338230-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH ALDH1A1 2717/4885TDP1 4053/4885ADRA2B 1916/4885
US-20030036552-A1 Novel compounds ARRB1, OPRK1, OPRM1 ALDH1A1 383/4885TDP1 2487/4885ADRA2B 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.